此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估不良事件及口服ABBV-1042在健康成年受试者体内代谢过程的研究

2026年10月14日 更新者:AbbVie

一项评估ABBV-1042在健康受试者中单次递增剂量给药的安全性、耐受性及药代动力学的1期、双盲、安慰剂对照、首次人体试验

This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.

研究概览

地位

完全的

研究类型

介入性

注册 (实际的)

36

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Illinois
      • Grayslake、Illinois、美国、60030
        • Acpru /Id# 279405

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • Body weight ˃ 45 kg at the time of screening and upon initial confinement.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG

Exclusion Criteria:

  • History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or upon initial confinement.
  • Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus, thyroid disorders), malignancy, hematological, immunological, neurological, or psychiatric disease that, , in the opinion of the investigator, could compromise either participant safety or the results of the trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:ABBV-1042 or Placebo-Group 1

Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

Oral Solution

Oral Solution

实验性的:ABBV-1042 or Placebo-Group 2

Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

Oral Solution

Oral Solution

实验性的:ABBV-1042 or Placebo-Group 3

Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

Oral Solution

Oral Solution

实验性的:ABBV-1042 or Placebo-Group 4

Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

Oral Solution

Oral Solution

实验性的:ABBV-1042 or Placebo-Group 5

Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

Oral Solution

Oral Solution

实验性的:ABBV-1042 or Placebo-Group 6

Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

Oral Solution

Oral Solution

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants Experiencing Adverse Events
大体时间:Up to approximately 32 days

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Up to approximately 32 days
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
大体时间:Up to approximately 3 days

Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

Up to approximately 3 days
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Up to approximately 3 days

The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

Up to approximately 3 days
Number of Participants with Abnormal Change in Physical Examinations
大体时间:Up to approximately 3 days

Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, and neurological systems will be assessed.

Up to approximately 3 days
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
大体时间:Up to approximately 3 days

12-lead resting ECG will be recorded.

Up to approximately 3 days
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
大体时间:Up to approximately 3 days

Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

Up to approximately 3 days
Maximum Plasma Concentration (Cmax) of ABBV-1042
大体时间:Up to approximately 3 days

Cmax of ABBV-1042

Up to approximately 3 days
Time to Cmax (Tmax) of ABBV-1042
大体时间:Up to approximately 3 days

Tmax of ABBV-1042

Up to approximately 3 days
Apparent terminal phase elimination constant (β) of ABBV-1042
大体时间:Up to approximately 3 days

β of ABBV-1042

Up to approximately 3 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1042
大体时间:Up to approximately 3 days

t1/2 of ABBV-1042

Up to approximately 3 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of ABBV-1042
大体时间:Up to approximately 3 days

AUCt of ABBV-1042

Up to approximately 3 days
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of ABBV-1042
大体时间:Up to approximately 3 days

AUCinf of ABBV-1042

Up to approximately 3 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:ABBVIE INC.、AbbVie

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年10月27日

初级完成 (实际的)

2026年9月18日

研究完成 (实际的)

2026年9月18日

研究注册日期

首次提交

2025年10月29日

首先提交符合 QC 标准的

2025年10月29日

首次发布 (实际的)

2025年10月30日

研究记录更新

最后更新发布 (实际的)

2026年10月15日

上次提交的符合 QC 标准的更新

2026年10月14日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • M25-818

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅